Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1

Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1

Abstract Resistance to docetaxel is a key problem in current prostate and breast cancer management. We have recently discovered a new molecular mechanism of prostate cancer docetaxel chemoresistance mediated by the mammalian target of rapamycin (mTOR)/sphingosine-kinase-1 (SK1) pathway. Here we inve...

Full description

Bibliographic Details
Main Authors: Heba Alshaker, Qi Wang, Torsten Böhler, Robert Mills, Mathias Winkler, Tawfiq Arafat, Yoshiaki Kawano, Dmitri Pchejetski
Format: Article
Language:English
Published: Nature Portfolio 2017-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-017-03728-3

Internet

https://doi.org/10.1038/s41598-017-03728-3

Similar Items